All news

InMed completes Mentari merger, shares to trade as MTRI

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

InMed Pharmaceuticals has completed its merger with privately held Mentari Therapeutics, with the combined company renamed Mentari Therapeutics, Inc. and shares expected to trade on Nasdaq as MTRI from November 9, 2026. Mentari previously raised roughly $490 million in private financings, including conversion of $50 million in convertible notes.

Read original source

INM company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.